Advances like immunotherapy and Antibody-Drug Conjugates (ADCs) in early-stage Triple-Negative Breast Cancer (TNBC) are so effective that fewer patients are relapsing. This success paradoxically makes it harder to enroll patients in trials for metastatic disease, shifting the trial population toward those with de novo metastatic cancer.

Pivotal trials for PARP inhibitor and ARPI combinations (e.g., PROPEL, MAGNITUDE) enrolled patients who were largely ARPI-naive. However, in modern practice, most patients receive an ARPI earlier in their treatment. This creates significant uncertainty about the benefit of these combinations for the majority of today's patients.

Despite statistically significant results, Akiso's successful China-only study faced skepticism due to its trial design. Exclusions of older patients and those with high bleeding risk cast doubt on whether the positive findings can be replicated in a diverse global population, posing a barrier to wider acceptance.

Exploratory analysis shows that while patients with 100% PTEN loss have a much worse natural history than those with 90% loss, the therapeutic effect of capivasertib is stable across this spectrum. The drug effectively targets the pathway regardless of the magnitude of loss, making it a robust option for this entire subgroup.

Even with positive results from two registrational Phase 3 trials, experts note a potential regulatory hurdle. The FDA has shown increasing concern over studies with a low proportion of patients from North America, a characteristic of these trials, potentially complicating an otherwise strong case for approval based on clinical merit.

When evaluating data like the impressive results from the SAC-TMT trial, clinicians must consider its geographic context. The study was conducted only in China, where trial outcomes are often more favorable than in broader global populations, warranting cautious optimism while awaiting global data.

The Avera trial's strong results for jiridestrant were overwhelmingly driven by patients with ESR1 mutations. Analysis revealed minimal benefit for patients without the mutation (wild-type), suggesting the mutation is a key predictive biomarker and the drug may not be for "all comers."

Emerging data suggests SCLC molecular subtypes (e.g., ASCL1, POU2F3) correlate with tarlatumab response. However, this research is too premature to guide clinical decision-making. Clinicians are strongly cautioned against altering patient management based on this "intriguing but not yet proven" subtype data.

An expert oncologist stated that if the drug is approved, he would not use it broadly. He would reserve it for a highly selective niche of high-risk patients who fail initial therapies and have specific NGS biomarkers. This signals a potential disconnect between a formal approval and real-world clinical utility.